{"id":23249,"date":"2023-05-31T19:42:11","date_gmt":"2023-05-31T14:12:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23249"},"modified":"2023-06-05T11:17:22","modified_gmt":"2023-06-05T05:47:22","slug":"dupixent-for-copd-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment","title":{"rendered":"ATS 2023 Updates: Dupixent &#8211; A Ray of Hope For Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD)"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases.<\/li>\n\n\n\n<li>DUPIXENT has the potential to be the first biologic with unprecedented&nbsp;and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduction in moderate to severe acute exacerbations of COPD, along with improvements in lung function<\/li>\n\n\n\n<li>DUPIXENT significantly improved quality of life, and reductions in the severity, with numerical improvements as early as 4 weeks after initiating treatment<\/li>\n<\/ul>\n\n\n\n<p>Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory disease that damages the lung and causes airflow blockage,&nbsp;leading to progressive lung function decline. Long-term exposure to toxic particles and smoking are the key <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-epidemiology\">risk factors for developing COPD<\/a>. Individuals often present with persistent cough and breathlessness that impair their ability to perform routine daily activities, besides leading to anxiety, depression, and sleep disturbances.&nbsp;<\/p>\n\n\n\n<p>As per Delveinsight\u2019s analysis, in 2022, there were approximately <strong>32 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\">diagnosed prevalent cases of COPD<\/a> among the 7MM countries, with the US accounting for approximately <strong>18 million<\/strong> cases.<\/p>\n\n\n\n<p>As the third most common cause of death, it is a global health concern that is notoriously difficult to treat due to its heterogeneity. Patients have, for a long, been struggling with the debilitating symptoms of this progressive disease and there have been limited incremental improvements in current treatment options over the last decade.&nbsp;<\/p>\n\n\n\n<p>The current pharmacotherapy regime for COPD consists of <strong>maintenance<\/strong> and <strong>reliever medications (bronchodilators)<\/strong>. Maintenance medications include inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), tiotropium, or fixed-dose combinations of ICS and LABA or ipratropium and albuterol while reliever medications include short-acting beta-agonist (SABA), oral corticosteroids (OCS), nebulized ipratropium, and antibiotics.&nbsp;<\/p>\n\n\n\n<p>Due to recurrent acute exacerbations that require systemic corticosteroid treatment and may lead to hospitalization or even death, the cost of treatment is mostly high and increases with disease progression, leading to significant health and economic burden.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/chronic-obstructive-pulmonary-disease-copd-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-1024x194.png\" alt=\"Chronic Obstructive Pulmonary Disease (COPD) Market Infographics\" class=\"wp-image-23257\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192106\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Infographics.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>There is a significant need for therapies that are disease-modifying and reduce exacerbations. While various therapies are being developed, <a href=\"https:\/\/www.delveinsight.com\/blog\/dupixent-market\" class=\"ek-link\"><strong>Sanofi and Regeneron\u2019s DUPIXENT (dupilumab)<\/strong><\/a> has become a frontrunner in the treatment of uncontrolled COPD with Type 2 inflammation.&nbsp;<\/p>\n\n\n\n<p>DUPIXENT, a fully human monoclonal antibody, is not an immunosuppressant. It inhibits the key central drivers of type 2 inflammation, the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways.&nbsp;<\/p>\n\n\n\n<p>At the recently held <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/american-thoracic-society-2023\"><strong>American Thoracic Society (ATS) International Conference 2023<\/strong><\/a><strong>, <\/strong>Sanofi presented results from <strong>NCT03930732,<\/strong> <strong>Phase III BOREAS trial <\/strong>evaluating the use of dupilumab compared to placebo in adults currently on maximum SoC triple inhaled therapy.&nbsp;<\/p>\n\n\n\n<p>In this trial (the first of two Phase III trials), 939 adults of the age group 40 to 80 years, who were either current or former smokers, were randomized to receive DUPIXENT (n=468) or placebo (n=471), every two weeks, to their standard-of-care inhaled therapy, during the 52-week treatment period. The trial enrolled individuals who had moderate to severe disease with evidence of type 2 inflammation, measured by blood eosinophils levels \u2265300 cells\/\u03bcL.&nbsp;<\/p>\n\n\n\n<p>All primary and key secondary endpoints were met, with DUPIXENT demonstrating unprecedented&nbsp;and potentially paradigm-shifting clinical results, at a magnitude never seen before with a biologic.&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>There was a <strong>30% reduction<\/strong> in the primary endpoint that evaluated the annualized rate of acute <strong>moderate or severe COPD exacerbations<\/strong>.&nbsp; The annualized rate of moderate or severe exacerbations was 0.78 with dupilumab and 1.10 with placebo.<\/li>\n\n\n\n<li>There was also rapid and <strong>significant improvement in lung function<\/strong> from baseline with the benefit being sustained through 52 weeks. The prebronchodilator FEV<sub>1<\/sub>&nbsp;increased from baseline to week 12 by a least-squares mean of 160ml with dupilumab and 77ml with placebo.<\/li>\n\n\n\n<li>There were significant improvements in quality of life and respiratory symptoms, with&nbsp;the St. George\u2019s Respiratory Questionnaire score improving by an LS mean of \u22129.7, and the Evaluating Respiratory Symptoms in COPD (E-RS\u2013COPD) improving by an LS mean of \u22122.7 with dupilumab.<\/li>\n\n\n\n<li>The safety profile was in accordance with the known profile of DUPIXENT in its approved indications.&nbsp; The overall rates of adverse events (AEs) were 77% for DUPIXENT and 76% for placebo, with the most commonly observed AEs being headache (8.1%), diarrhea (5.3%), and back pain (5.1%). AEs leading to deaths were well-adjusted between the two arms (1.7% placebo, 1.5% DUPIXENT).<\/li>\n<\/ul>\n\n\n\n<p>While many investigational treatments have failed to demonstrate significant clinical outcomes leaving difficult-to-treat patients with limited treatment options, COPD caregivers can now breath a sigh of relief.&nbsp;<\/p>\n\n\n\n<p><strong><em>\u201cThe findings of the BOREAS trial contribute to the growing form of evidence that supports as-needed anti-inflammatory therapy&#8217;s effectiveness in COPD. DUPIXENT has the potential to revolutionize the <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\"><strong><em>COPD treatment paradigm<\/em><\/strong><\/a><strong><em> by lowering the risk of severe exacerbations in COPD patients,<\/em><\/strong> <strong><em>significantly improving respiratory symptoms. \u201d<\/em><\/strong><\/p>\n\n\n\n<p>Sanofi and Regeneron\u2019s Dupixent is already churning up sales with considerable momentum across several indications and COPD will be another crowing stroke for the drug. The second, replicate Phase III trial of Dupixent in COPD (NOTUS) is ongoing with data anticipated by 2024, which will be followed by regulatory submission in the US and EU.&nbsp;COPD is a complex condition and considering GSK\u2019s NUCALA and AstraZeneca\u2019s FASENRA struggles with FDA approvals, DUPIXENT\u2019s success will be exciting to watch. <strong>According to DelveInsights\u2019 analysis, the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-pipeline-insight\"><strong>COPD drug<\/strong><\/a><strong> will have a moderate to fast uptake, attaining its peak share 6 years after launch in 2024.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-1024x256.png\" alt=\"Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics\" class=\"wp-image-23256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31192023\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Dynamics.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory disease that damages the lung and causes airflow blockage,&nbsp;leading to progressive lung function decline. Long-term exposure to toxic particles and smoking are the key risk factors for developing COPD. Individuals often present with persistent cough and breathlessness that impair their ability to perform routine daily activities, [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":23252,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1811,20742,20743,719,20745,6893,6894,718,4799],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-23249","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-american-cancer-society","tag-ats","tag-ats-2023","tag-chronic-obstructive-pulmonary-disease","tag-chronic-obstructive-pulmonary-disease-copd","tag-chronic-obstructive-pulmonary-disease-market","tag-chronic-obstructive-pulmonary-disease-therapy","tag-copd","tag-dupixent","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Potential of Dupixent for COPD | ATS Conference Coverage, 2023<\/title>\n<meta name=\"description\" content=\"DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD. DUPIXENT results\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potential of Dupixent for COPD | ATS Conference Coverage, 2023\" \/>\n<meta property=\"og:description\" content=\"DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD. DUPIXENT results\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-31T14:12:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-05T05:47:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Potential of Dupixent for COPD | ATS Conference Coverage, 2023","description":"DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD. DUPIXENT results","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment","og_locale":"en_US","og_type":"article","og_title":"Potential of Dupixent for COPD | ATS Conference Coverage, 2023","og_description":"DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD. DUPIXENT results","og_url":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-05-31T14:12:11+00:00","article_modified_time":"2023-06-05T05:47:22+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment","url":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment","name":"Potential of Dupixent for COPD | ATS Conference Coverage, 2023","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook.png","datePublished":"2023-05-31T14:12:11+00:00","dateModified":"2023-06-05T05:47:22+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD. DUPIXENT results","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook.png","width":1200,"height":800,"caption":"Chronic Obstructive Pulmonary Disease (COPD) Market Outlook"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31191837\/Chronic-Obstructive-Pulmonary-Disease-COPD-Market-Outlook-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">American Cancer Society<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ATS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ATS 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease (COPD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">COPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupixent<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">American Cancer Society<\/span>","<span class=\"advgb-post-tax-term\">ATS<\/span>","<span class=\"advgb-post-tax-term\">ATS 2023<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease (COPD)<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease market<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease therapy<\/span>","<span class=\"advgb-post-tax-term\">COPD<\/span>","<span class=\"advgb-post-tax-term\">Dupixent<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 31, 2023","modified":"Updated on Jun 5, 2023"},"absolute_dates_time":{"created":"Posted on May 31, 2023 7:42 pm","modified":"Updated on Jun 5, 2023 11:17 am"},"featured_img_caption":"Chronic Obstructive Pulmonary Disease (COPD) Market Outlook","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23249"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23249\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23252"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23249"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23249"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}